Press Release May 06 2022
Filed with NSE · · 2 pages · English
Summary by 6ix AI
Zydus Lifesciences Limited has issued a press release regarding its recent approval from the USFDA. The approval is for Selexipag Tablets, which are used to treat pulmonary arterial hypertension. The drug will be manufactured at the company's facility in Ahmedabad. This marks a significant milestone as the group now has numerous approvals and has filed many ANDAs since its inception.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Press Release May 03 2022
- Press Release Apr 26 2022
- Press Release Apr 25 2022
- Press Release Apr 18 2022
- Press Release Apr 13 2022
Later from Zydus Lifesciences
- Press Release May 13 2022
- Press Release May 26 2022
- Press Release May 27 2022
- Press Release Jun 06 2022
- Press Release Jun 07 2022
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences